These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31693734)

  • 1. Treatment of Rituximab-induced Crohn's Disease With Ustekinumab Induction and Long-term Maintenance of Remission.
    Shankar U; Vijayasekar K; Bansal R; Walfish A
    Inflamm Bowel Dis; 2020 Jan; 26(1):e3. PubMed ID: 31693734
    [No Abstract]   [Full Text] [Related]  

  • 2. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
    Feagan BG; Sandborn WJ; Gasink C; Jacobstein D; Lang Y; Friedman JR; Blank MA; Johanns J; Gao LL; Miao Y; Adedokun OJ; Sands BE; Hanauer SB; Vermeire S; Targan S; Ghosh S; de Villiers WJ; Colombel JF; Tulassay Z; Seidler U; Salzberg BA; Desreumaux P; Lee SD; Loftus EV; Dieleman LA; Katz S; Rutgeerts P;
    N Engl J Med; 2016 Nov; 375(20):1946-1960. PubMed ID: 27959607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous ustekinumab reinduction as a Crohn's disease rescue strategy following a secondary non-response.
    Vázquez Morón JM; Rodríguez Moncada R; Pallarés Manrique H
    Rev Esp Enferm Dig; 2019 Sep; 111(9):721. PubMed ID: 31333034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
    Sandborn WJ; Rutgeerts P; Gasink C; Jacobstein D; Zou B; Johanns J; Sands BE; Hanauer SB; Targan S; Ghosh S; de Villiers WJS; Colombel JF; Feagan BG
    Aliment Pharmacol Ther; 2018 Jul; 48(1):65-77. PubMed ID: 29797519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Ustekinumab on Extraintestinal Diseases in Refractory Crohn's Disease.
    Tursi A; Mocci G; Maconi G
    J Crohns Colitis; 2021 Aug; 15(8):1399-1400. PubMed ID: 33580249
    [No Abstract]   [Full Text] [Related]  

  • 6. Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
    Sandborn WJ; Gasink C; Gao LL; Blank MA; Johanns J; Guzzo C; Sands BE; Hanauer SB; Targan S; Rutgeerts P; Ghosh S; de Villiers WJ; Panaccione R; Greenberg G; Schreiber S; Lichtiger S; Feagan BG;
    N Engl J Med; 2012 Oct; 367(16):1519-28. PubMed ID: 23075178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IM-UNITI at Three Years: Stellar Stelara® or Stardust? The Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
    Travis S
    J Crohns Colitis; 2020 Jan; 14(1):1-3. PubMed ID: 31605526
    [No Abstract]   [Full Text] [Related]  

  • 8. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
    Hanauer SB; Sandborn WJ; Feagan BG; Gasink C; Jacobstein D; Zou B; Johanns J; Adedokun OJ; Sands BE; Rutgeerts P; de Villiers WJS; Colombel JF; Ghosh S
    J Crohns Colitis; 2020 Jan; 14(1):23-32. PubMed ID: 31158271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.
    Yoshihara T; Shinzaki S; Amano T; Iijima H; Takehara T; Inoue N; Uchino M; Esaki M; Kobayashi T; Saruta M; Sugimoto K; Nakamura S; Hata K; Hirai F; Hiraoka S; Fujii T; Matsuura M; Matsuoka K; Watanabe K; Nakase H; Watanabe M
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1744-1753. PubMed ID: 33450096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies.
    Macaluso FS; Maida M; Ventimiglia M; Cottone M; Orlando A
    Expert Opin Biol Ther; 2020 Feb; 20(2):193-203. PubMed ID: 31859538
    [No Abstract]   [Full Text] [Related]  

  • 11. Crohn's Disease Following Rituximab Treatment for Follicular Lymphoma in a Patient with Synchronous Gastric Signet Ring Cells Carcinoma: A Case Report and Literature Review.
    Cavalcanti E; Armentano R; Lolli I
    Cancer Res Treat; 2020 Oct; 52(4):1291-1295. PubMed ID: 32683839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab to treat Crohn's disease.
    Gisbert JP; Chaparro M
    Gastroenterol Hepatol; 2017 Dec; 40(10):688-698. PubMed ID: 29042094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
    Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
    Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ustekinumab: a novel therapeutic option in Crohn's disease.
    Simon EG; Samuel S; Ghosh S; Moran GW
    Expert Opin Biol Ther; 2016 Aug; 16(8):1065-74. PubMed ID: 27341173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crohn's disease following rituximab treatment in a patient with refractory nephrotic syndrome.
    Morita K; Shibano T; Maekawa K; Hattori M; Hida N; Nakamura S; Takeshima Y
    CEN Case Rep; 2019 Feb; 8(1):55-60. PubMed ID: 30251194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
    Adedokun OJ; Xu Z; Gasink C; Jacobstein D; Szapary P; Johanns J; Gao LL; Davis HM; Hanauer SB; Feagan BG; Ghosh S; Sandborn WJ
    Gastroenterology; 2018 May; 154(6):1660-1671. PubMed ID: 29409871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elderly-onset Crohn's disease remarkably responsive to ustekinumab: a case report.
    Iwamoto M; Kato K; Moriyama M
    Int J Colorectal Dis; 2020 Feb; 35(2):355-359. PubMed ID: 31848740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
    Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
    J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ustekinumab for Resistant Pediatric Crohn Disease.
    Rinawi F; Rosenbach Y; Assa A; Shamir R
    J Pediatr Gastroenterol Nutr; 2016 Apr; 62(4):e34-5. PubMed ID: 25023579
    [No Abstract]   [Full Text] [Related]  

  • 20. Preliminary experience of maintenance treatment with intravenous ustekinumab as a rescue treatment for loss of response to subcutaneous doses.
    Pérez Valle I; Varela Trastoy P; Mancebo Mata A
    Rev Esp Enferm Dig; 2021 Mar; 113(3):186-188. PubMed ID: 33222477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.